UBS O'Connor’s Heron Therapeutics HRTX Stock Holding History

UBS O'Connor’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,145,000	Closed	-$28.3M	–	978
2022 Q2	$28.3M	Buy	+10,145,000	New	+$40.7M	0.29%	40
2022 Q1	–	Sell	-8,275,000	Closed	-$75.6M	–	96
2021 Q4	$75.6M	Buy	8,275,000 +1,641,084	+25%	+$16.8M	0.73%	16
2021 Q3	$70.9M	Buy	6,633,916 +2,208,916	+50%	+$26.9M	0.56%	20
2021 Q2	$68.7M	Buy	4,425,000 +2,100,000	+90%	+$33.4M	0.61%	23
2021 Q1	$37.7M	Buy	2,325,000 +1,725,000	+288%	+$30.8M	0.54%	21
2020 Q4	$12.7M	Sell	600,000 -50,000	-8%	-$869K	0.26%	60
2020 Q3	$9.63M	Sell	650,000 -25,000	-4%	-$390K	0.24%	61
2020 Q2	$9.93M	Sell	675,000 -725,000	-52%	-$11.9M	0.22%	109
2020 Q1	$16.4M	Buy	+1,400,000	New	+$26.3M	0.34%	61
2019 Q3	–	Sell	-100,000	Closed	-$1.86M	–	339
2019 Q2	$1.86M	Buy	+100,000	New	+$2M	0.04%	149

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

UBS O'Connor's HRTX Position: Q3 2022 in Review

UBS O'Connor sold out of Heron Therapeutics (HRTX) in Q3 2022, closing a stake of 10,145,000 shares — an estimated $28.3M sold.

UBS O'Connor first reported a position in HRTX in Q2 2019 and held it in 10 quarters. The position peaked at $75.6M in Q4 2021. 186 funds tracked by Wall St. Rank hold HRTX as of Q3 2022.

UBS O'Connor reported no remaining Heron Therapeutics position as of Q3 2022 after selling out during the quarter.
UBS O'Connor sold 10,145,000 Heron Therapeutics shares in Q3 2022, an estimated $28.3M.
UBS O'Connor first reported a position in Heron Therapeutics in Q2 2019 and held it in 10 quarters.
UBS O'Connor's Heron Therapeutics position peaked at $75.6M in Q4 2021.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2022.

Based on UBS O'Connor's 13F filing for Q3 2022, filed 14 Nov 2022.